# Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)

> **NCT01509625** · — · COMPLETED · sponsor: **Isabel Blancas** · enrollment: 272 (actual)

## Conditions studied

- Malignant Neoplasm of Breast Stage IV

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT01509625
- **Lead sponsor:** Isabel Blancas
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-03
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2016-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01509625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01509625, "Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01509625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*